NICE Nod To Lucentis For ME Raises Unlicensed Comparator Issue
This article was originally published in The Pink Sheet Daily
The U.K.’s cost watchdog NICE has waved through Novartis’ Lucentis for macular edema after the Swiss manufacturer offered a discount.
You may also be interested in...
NICE has given the thumbs-up to Bayer’s Eylea in wet AMD, but its impressive cost-effectiveness could spell trouble for Novartis’ Lucentis in the long run.
NICE has knocked back Avastin for ovarian cancer due to high cost, but Roche may have a plausible market strategy in place for the drug in the UK.
Roche’s extremely high price for Avastin results in yet another knock-back by Britain’s NICE, this time for advanced ovarian cancer.